CN110772611A - Traditional Chinese medicine composition for regulating gout - Google Patents

Traditional Chinese medicine composition for regulating gout Download PDF

Info

Publication number
CN110772611A
CN110772611A CN201911288296.0A CN201911288296A CN110772611A CN 110772611 A CN110772611 A CN 110772611A CN 201911288296 A CN201911288296 A CN 201911288296A CN 110772611 A CN110772611 A CN 110772611A
Authority
CN
China
Prior art keywords
parts
traditional chinese
chinese medicine
medicine composition
gout
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201911288296.0A
Other languages
Chinese (zh)
Inventor
赵洪勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201911288296.0A priority Critical patent/CN110772611A/en
Publication of CN110772611A publication Critical patent/CN110772611A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/536—Prunella or Brunella (selfheal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
    • A61K36/605—Morus (mulberry)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a traditional Chinese medicine composition for regulating gout. The traditional Chinese medicine composition for conditioning gout comprises the following components in parts by weight: 5-15 parts of pseudo-ginseng; 5-15 parts of angelica; 5-15 parts of ligusticum wallichii; 5-15 parts of radix bupleuri; 5-15 parts of semen cassiae; 5-15 parts of chrysanthemum; 5-15 parts of selfheal; 5-15 parts of mulberry leaves; 5-15 parts of lophatherum gracile; 5-15 parts of plantain herb. The traditional Chinese medicine composition for conditioning gout, provided by the invention, can be used for fundamentally conditioning the body and solving the gout problem, so that the traditional Chinese medicine composition is not used for medicine and can be used for recovering the body function, and the traditional Chinese medicine composition has no side effect.

Description

Traditional Chinese medicine composition for regulating gout
Technical Field
The invention relates to the field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for regulating gout.
Background
At present, the blood pressure of a normal person fluctuates within a certain range along with the changes of internal and external environments. In the whole population, the blood pressure level gradually increases with age, the systolic pressure is more obvious, but the diastolic pressure shows a descending trend after the age of 50, and the pulse pressure difference is increased. In recent years, people have increasingly deep knowledge on the effects of multiple risk factors of cardiovascular diseases and the protection of target organs of heart, brain and kidney, the diagnosis standard of hypertension is continuously adjusted, and at present, patients with the same blood pressure level are considered to have different cardiovascular disease risks, so that the concept of blood pressure stratification is provided, namely, the patients with different cardiovascular disease risks are different in proper blood pressure level.
The symptoms of hypertension vary from person to person. Early stages may be asymptomatic or not obvious, and only an increase in blood pressure occurs after exertion, mental stress, mood swings, and returns to normal after rest. As the course of the disease extends, blood pressure rises markedly and continuously, and various symptoms gradually appear, which is called slow-progression hypertension. Common clinical symptoms of the slow-type hypertension include headache, dizziness, inattention, hypomnesis, numbness of limbs, nocturia, palpitation, chest distress, hypodynamia and the like. When blood pressure suddenly rises to a certain degree, symptoms such as severe headache, vomiting, palpitation, dizziness and the like can even appear, and unconsciousness and convulsion can happen in severe cases. This is a rapidly progressive hypertension and critical hypertension, and most of them will cause serious damage and pathological changes of organs such as heart, brain, kidney, etc. in a short period, such as apoplexy, myocardial infarction, renal failure, etc.
At present, the medicaments for treating hypertension are mainly western medicaments, such as hydrochlorothiazide, amiloride, furosemide and the like. The medicines not only have human body dependence, but also bring great side effect to the collective body. Some traditional Chinese medicine preparations for conditioning hypertension are also available in the market in recent years, mainly take sedation, yang suppressing, blood cooling and nerve calming as main products, and have an unclear conditioning effect on hypertension.
For the treatment of diabetes, chemical drugs mainly use the combination of injected insulin, sulfonylurea drugs and biguanide hypoglycemic drugs, etc., although the effect is good, the side effects are many, generally expressed as: hypoglycemia, local subcutaneous lipoatrophy or hyperplasia, insulin allergy, insulin edema, ametropia, weight gain, damage to liver and kidney, etc. These side effects cause great pain to the diabetic.
Disclosure of Invention
Aiming at the defects in the prior art, the traditional Chinese medicine composition for regulating gout provided by the invention solves the technical problems and provides the traditional Chinese medicine composition for regulating gout.
In order to achieve the purpose, the invention provides the following technical scheme:
the traditional Chinese medicine composition for conditioning gout comprises the following components in parts by weight: 5-15 parts of pseudo-ginseng; 5-15 parts of angelica; 5-15 parts of ligusticum wallichii; 5-15 parts of radix bupleuri; 5-15 parts of semen cassiae; 5-15 parts of chrysanthemum; 5-15 parts of selfheal; 5-15 parts of mulberry leaves; 5-15 parts of lophatherum gracile; 5-15 parts of plantain herb.
A traditional Chinese medicine composition for regulating gout comprises the following components in parts by weight: 10 parts of pseudo-ginseng; 10 parts of angelica; 10 parts of ligusticum wallichii; 10 parts of radix bupleuri; 10 parts of cassia seed; 10 parts of chrysanthemum; 10 parts of selfheal; 10 parts of mulberry leaves; 10 parts of lophatherum gracile; 10 parts of plantain herb.
A traditional Chinese medicine composition for regulating gout comprises the following components in parts by weight: 12 parts of pseudo-ginseng; 13 parts of angelica; 10 parts of ligusticum wallichii; 7 parts of radix bupleuri; 8 parts of semen cassiae; 11 parts of chrysanthemum; 13 parts of selfheal; 14 parts of mulberry leaves; 13 parts of lophatherum gracile; 12 parts of plantain herb.
A traditional Chinese medicine composition for conditioning gout comprises the following steps:
the method comprises the following steps: supporting the raw materials according to the proportion to form 100-150-mesh powder;
step two: the powder is prepared into an oral preparation according to the conventional process of pharmacy and auxiliary materials.
The invention has the beneficial effects that: the traditional Chinese medicine composition for conditioning gout provided by the invention is a pure traditional Chinese medicine product, has the effects of clearing heat and removing toxicity, promoting diuresis and reducing turbidity, removing blood stasis and dissipating stagnation, and relieving swelling and pain, and can effectively relieve local swelling and severe pain of acute gout single joints; or chronic gout joint pain is not continuously relieved, local redness or swelling at the pain part, or gout nodules are formed; or uric acid renal damage without side effects.
For a better understanding of the features and technical content of the present invention, refer to the following detailed description of the invention.
Detailed Description
To further illustrate the technical means adopted by the present invention and the effects thereof, the following detailed description is given with reference to the preferred embodiments of the present invention.
A traditional Chinese medicine composition for regulating gout comprises, by weight, 5-15 parts of pseudo-ginseng, 5-15 parts of angelica sinensis; 5-15 parts of ligusticum wallichii; 5-15 parts of radix bupleuri; 5-15 parts of semen cassiae; 5-15 parts of chrysanthemum; 5-15 parts of selfheal; 5-15 parts of mulberry leaves; 5-15 parts of lophatherum gracile; 5-15 parts of plantain herb.
Example 1:
a traditional Chinese medicine composition for regulating gout comprises the following components in parts by weight: 10 parts of pseudo-ginseng; 10 parts of angelica; 10 parts of ligusticum wallichii; 10 parts of radix bupleuri; 10 parts of cassia seed; 10 parts of chrysanthemum; 10 parts of selfheal; 10 parts of mulberry leaves; 10 parts of lophatherum gracile; 10 parts of plantain herb.
A traditional Chinese medicine composition for conditioning gout comprises the following steps:
the method comprises the following steps: supporting the raw materials in proportion to 100-mesh powder;
step two: the powder is prepared into an oral preparation according to the conventional process of pharmacy and auxiliary materials.
Example 2:
a traditional Chinese medicine composition for regulating gout comprises the following components in parts by weight: 12 parts of pseudo-ginseng; 13 parts of angelica; 10 parts of ligusticum wallichii; 7 parts of radix bupleuri; 8 parts of semen cassiae; 11 parts of chrysanthemum; 13 parts of selfheal; 14 parts of mulberry leaves; 13 parts of lophatherum gracile; 12 parts of plantain herb.
A traditional Chinese medicine composition for conditioning gout comprises the following steps:
the method comprises the following steps: supporting the raw materials into 120-mesh powder according to the proportion;
step two: the powder is prepared into an oral preparation according to the conventional process of pharmacy and auxiliary materials.
The traditional Chinese medicine composition has good curative effect on gout and low recurrence rate, and provides a clinical experiment for proving the effect of the medicine.
150 gout patients are selected, wherein the 150 gout patients are 30-65 years old, the disease course is 1-10 years old, 89 men and 61 women.
1. Test method
According to the illness state of a patient, the dosage can be correspondingly increased or decreased under the condition of ensuring that the proportion of each raw material is not changed, but the dosage variation range is not too large and should not exceed the dosage by 15 percent. The using method comprises the following steps: the traditional Chinese medicine composition is taken twice a day, 30g of the traditional Chinese medicine composition is used for each time according to the crude drug weight, and the traditional Chinese medicine composition is taken after meals, and a treatment course is 20 days.
2. Standard of therapeutic effect
(1) And (3) curing: the clinical symptoms of the joint such as red, swollen, hot and painful symptoms disappear, the joint moves freely, and the blood uric acid returns to normal;
(2) the method has the following advantages: the clinical symptoms of the joint are red, swollen, hot and painful, the moving part is recovered, and the blood uric acid level is reduced;
(3) and (4) invalidation: the joint clinical symptoms are not obviously improved, and the blood uric acid level is not obviously changed.
4. The treatment effect is as follows: clinical observation shows that the clinical cure or effectiveness can be achieved after 2-3 treatment courses with short disease course; the long course of disease requires 5-6 courses of treatment; after statistics, the clinical cure rate reaches 88%, the total effective rate is 93%, and the ineffective rate is only 7%. Half a year later follow-up was performed on cured patients with a recurrence rate of only 0.
Typical cases are as follows:
the Hu master, 56 years old, has 6 calendar history cases, Shenzhen marketer, professional engineer, and has been in the normal range for conditioning for six months by using the patent of the invention.
Wu Mr. 44 years old, Beijing, suffered from ventilation, had no change in direct medication conditioning, and after six months of conditioning, the medicine is discontinued and no medicine is taken.
The above description is only for the specific embodiments of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can easily conceive of the changes or substitutions within the technical scope of the present invention, and all the changes or substitutions should be covered within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the claims.

Claims (4)

1. The traditional Chinese medicine composition for conditioning gout is characterized by comprising the following components in parts by weight: 5-15 parts of pseudo-ginseng; 5-15 parts of angelica; 5-15 parts of ligusticum wallichii; 5-15 parts of radix bupleuri; 5-15 parts of semen cassiae; 5-15 parts of chrysanthemum; 5-15 parts of selfheal; 5-15 parts of mulberry leaves; 5-15 parts of lophatherum gracile; 5-15 parts of plantain herb.
2. The traditional Chinese medicine composition for regulating gout according to claim 1, which is characterized by comprising the following components in parts by weight: 10 parts of pseudo-ginseng; 10 parts of angelica; 10 parts of ligusticum wallichii; 10 parts of radix bupleuri; 10 parts of cassia seed; 10 parts of chrysanthemum; 10 parts of selfheal; 10 parts of mulberry leaves; 10 parts of lophatherum gracile; 10 parts of plantain herb.
3. The traditional Chinese medicine composition for regulating gout according to claim 1, which is characterized by comprising the following components in parts by weight: 12 parts of pseudo-ginseng; 13 parts of angelica; 10 parts of ligusticum wallichii; 7 parts of radix bupleuri; 8 parts of semen cassiae; 11 parts of chrysanthemum; 13 parts of selfheal; 14 parts of mulberry leaves; 13 parts of lophatherum gracile; 12 parts of plantain herb.
4. The traditional Chinese medicine composition for regulating gout according to claim 1, comprising the following steps of:
the method comprises the following steps: supporting the raw materials according to the proportion to form 100-150-mesh powder;
step two: the powder is prepared into an oral preparation according to the conventional process of pharmacy and auxiliary materials.
CN201911288296.0A 2019-12-13 2019-12-13 Traditional Chinese medicine composition for regulating gout Pending CN110772611A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911288296.0A CN110772611A (en) 2019-12-13 2019-12-13 Traditional Chinese medicine composition for regulating gout

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911288296.0A CN110772611A (en) 2019-12-13 2019-12-13 Traditional Chinese medicine composition for regulating gout

Publications (1)

Publication Number Publication Date
CN110772611A true CN110772611A (en) 2020-02-11

Family

ID=69394561

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911288296.0A Pending CN110772611A (en) 2019-12-13 2019-12-13 Traditional Chinese medicine composition for regulating gout

Country Status (1)

Country Link
CN (1) CN110772611A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101926855A (en) * 2010-08-25 2010-12-29 肖富洲 Medicinal tea for reducing uric acid of patient with gout
CN102133271A (en) * 2011-02-24 2011-07-27 刘爱民 Medicinal tea for curing gout
CN104366636A (en) * 2014-10-30 2015-02-25 袁丁 Gynura procumbens compound preparation as well as preparation method and application thereof
CN106266776A (en) * 2016-09-18 2017-01-04 贵阳中医学院 A kind of teabag of patient with gout
CN110420297A (en) * 2019-07-30 2019-11-08 于凤云 A kind of Chinese materia medica preparation for anti-trioxypurine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101926855A (en) * 2010-08-25 2010-12-29 肖富洲 Medicinal tea for reducing uric acid of patient with gout
CN102133271A (en) * 2011-02-24 2011-07-27 刘爱民 Medicinal tea for curing gout
CN104366636A (en) * 2014-10-30 2015-02-25 袁丁 Gynura procumbens compound preparation as well as preparation method and application thereof
CN106266776A (en) * 2016-09-18 2017-01-04 贵阳中医学院 A kind of teabag of patient with gout
CN110420297A (en) * 2019-07-30 2019-11-08 于凤云 A kind of Chinese materia medica preparation for anti-trioxypurine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
苏小军: "《新编中医内科学》", 30 June 2018 *

Similar Documents

Publication Publication Date Title
Jouad et al. Hypoglycaemic effect of Rubus fructicosis L. and Globularia alypum L. in normal and streptozotocin-induced diabetic rats
CN105769789A (en) Clozapine tablets for treating schizophrenia and preparation method thereof
CN110917272A (en) Traditional Chinese medicine formula for curing diabetes and complications thereof
CN106421581A (en) Biological traditional Chinese medicine for oral administration for treating diabetes and preparation method thereof
CN103055176B (en) Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof
CN102940693B (en) Medicine composition for treating diabetic foot
CN110917300A (en) Traditional Chinese medicine composition for regulating hypertension and diabetes
CN110772611A (en) Traditional Chinese medicine composition for regulating gout
CN102940677B (en) Medicine composition for treating diabetic foot
CN102940743B (en) Medicine composition for treating diabetic foot
WO2021007934A1 (en) Application of liquor product with soaked lucilia sericata for treating diabetes
WO2021007933A1 (en) Application of maggots in treatment of diabetes
CN101342208B (en) Chinese medicinal composition for treating coronary disease, stenocardia, arrhythmia and preparation method thereof
CN104225074A (en) Traditional Chinese medicinal pill for treating diabetes
CN114617939B (en) Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy
CN108310356A (en) A kind of pharmaceutical composition and preparation method thereof for treating vascular conditions
CN103656488B (en) A kind of Chinese medicine composition for the treatment of diabetes complicated diabetic foot
CN102727570A (en) External pharmaceutical composition for treating diabetic foot as well as preparation method and application of external pharmaceutical composition
CN102940671B (en) Medicine composition for treating diabetic foot
CN103055159B (en) Medicine for treating hypertension
CN1124140C (en) Chinese medicine Tangzhi'an for treating peripheral nerve lesion of diabetes
CN102380017A (en) Medicament for treating diabetes and preparation method of medicament
CN109420039A (en) A kind of Chinese medicine treated diabetes and merge hypoglycemia
CN106177331A (en) A kind of Chinese medicine treating hypertension
CN106266741A (en) A kind of preparation method for treating psoriasic Chinese medicine formula

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200211